- Peak Oil Closer Than IEA Forecasts Show: Report
- UK Most at Risk of Losing Top Credit Rating: Fitch
- GM CEO Starts Charm Tour at Opel in Germany
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Bad Debt Weighs on Barclays Earnings
- HSBC Operating Profit Beats, US Bad Debts Slip
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
- 'Modern Warfare 2': Biggest Entertainment Event?
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Future of Marketing
- Mad Mail: Buy the Berkshire Hathaway Split?
- European Commission Objects to Sun Micro-Oracle Deal
- GM CEO Starts Opel Charm Tour in Germany
- Framed for Porn – By a PC Virus
- A Year on, China's Stimulus Postpones its Problems
- Israel: Leader of Business Innovation
Text Size 
An analyst sounded a warning note on shares of biotechnology company Dendreon on Monday, which have more than tripled in value since March 30, but the stock continued to rise.
A Food and Drug Administration panel endorsed Provenge, a prostate cancer vaccine, on March 30, saying there was evidence the drug could be an effective cancer fighter. The agency usually follows panel recommendations in evaluating new drug applications.
Brean Murray Carret & Co. analyst Jonathan Aschoff said the FDA would set a "dangerous double standard" by approving Provenge, which did not meet its primary goal in two phase III trials. He said the FDA rejected Pharmacyclics' new drug application for Xcytrin for not reaching its goals, but agreed to review the Provenge application.
Aschoff has "Sell" rating and a price target of $1.50 for shares of Seattle-based Dendreon, implying the stock will lose 91.7 percent of its value in the next year.
Five of the nine analysts reporting to Thomson Financial rate Dendreon stock at "Buy" or the equivalent. Two analysts rate it at "Neutral"-equivalent and two at "Sell"-equivalent.
Dendreon were up [DNDN
Loading...
()
] on the Nasdaq Stock Market. The stock hit a new all-time high of $21 shortly after the open Monday.
Print
Email
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- Software, biotech firms, even banks are watching a particular Supreme Court argument today.
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- The health care reform bill that passed the House on Saturday will have a much harder time in the Senate.
Data is a real-time snapshot *Data is delayed at least 15 minutes